Target intelligence / Profile preview

ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2)

Target
ADAM20P2
Molecular classification
Other (pseudogene)
01

Overview

ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2) is a pseudogene related to the ADAM (A Disintegrin And Metalloproteinase) family, named for its sequence similarity to ADAM20. Pseudogenes like ADAM20P2 are genomic DNA sequences similar to normal genes but are non-functional; they do not encode a functional protein due to disruptions such as insertions, deletions, or premature stop codons[3]. There is no evidence that ADAM20P2 produces a functional protein product, contributes to canonical ADAM family activities (such as cell adhesion or proteolysis), or plays a direct role in human disease or therapeutic targeting. The ADAM family itself is known for membrane-anchored proteins involved in proteolysis and cell signaling, but ADAM20P2 does not code for such a protein[1][3]. This entry is a pseudogene and therefore is not an active protein or typical drug target (enzyme, receptor, etc.), and its inclusion as a therapeutic target is usually incorrect[3]. No drug interactions, mechanisms of action, biomarker status, or safety concerns have been associated with this sequence[3]. If you need information on the closely related functional gene/protein ADAM20, which does encode a metalloprotease and participates in cell adhesion and proteolysis, please clarify, as ADAM20P2 specifically is a pseudogene and not a protein-coding therapeutic target[1][3].

Other names
ADAM20 pseudogene 2

Beyond the preview

Go deeper on ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADAM metallopeptidase domain 20 pseudogene 2 (ADAM20P2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call